KELUN PHARMA(SZ:002422) Shang Hai Zheng Quan Bao·2025-12-11 19:21Group 1 - The core point of the announcement is that Sichuan Kelun Pharmaceutical Co., Ltd. plans to implement a share incentive plan for its subsidiary, Kelun Biotech, to attract and retain core talent and align interests among shareholders, the company, and key personnel [1][10]. Group 2 - The incentive plan will grant restricted share units, with a maximum of 3,500,000 H-shares to be issued, representing approximately 1.5% of the total shares of Kelun Biotech on the date of approval [2]. - The plan aims to establish a long-term incentive mechanism to support the strategic and operational goals of Kelun Biotech [3]. - The plan will be effective for ten years from the adoption date, with no new share awards to be granted after the expiration [3]. Group 3 - Eligible participants include directors and employees of Kelun Biotech and its subsidiaries, with selection based on performance, tenure, and contributions [4]. - The purchase price for the shares is set at RMB 1.00 per share, with a vesting period of four years, and performance targets must be met for the shares to vest [6]. - The management of the incentive plan will be overseen by the board of directors or authorized representatives of Kelun Biotech [7]. Group 4 - The incentive plan has been approved by the board of directors of Kelun Biotech but requires shareholder approval and listing approval from the Hong Kong Stock Exchange [9]. - The implementation of the plan is expected to enhance the core competitiveness and sustainable development of Kelun Biotech without adversely affecting the financial status or operational results of the parent company [10].